Interestingly, we found that low CASP6 expression showed higher dysfunction and a lower exclusion score using the TIDE algorithm (p < 0.001), suggesting that high CASP6 expression may benefit from immunotherapy in CRC (Figure 13C). Here, CASP6 is linked to colorectal carcinoma.